top of page
Depositphotos_27799605_xl-2015_edited.jpg

Heart and Vascular

Sapere Bio is developing a series of products to optimize critical treatment decisions for patients with heart and vascular disease, beginning with those that require cardiac surgery and other interventions that put them at-risk of treatment-related adverse events, prolonged recovery, and long-term compromise.

AKI-Sapere

AKI-Sapere is a pre-operative blood test that uses senescence to stratify patients by risk of acute kidney injury (AKI) before cardiac surgery. 

Unpredictable kidney injury

Blurred hospital images, Patient bed in the hospital, Hospital cleaning, Hospital disinfec
dreamstime_l_119817044.jpg
Depositphotos_332090160_xl-2015.jpg

30% of cardiac surgery patients experience AKI with devastating consequences.

Surgeons cannot predict which patients are vulnerable based on common clinical variables 

(sCr, eGFR, diabetes, age).

AKI interventions are limited and applied post-op, long after injury.

​

Preventable with AKI-Sapere

Doctor with Files
Performing Surgery
Depositphotos_294241110_xl-2015.jpg

80% of AKI cases can be predicted before surgery.

Pre- and intra-operative interventions can prevent or reduce the severity of AKI.

Patients, physicians, and hospitals benefit from better surgical outcomes.

​

Studied at leading cardiovascular centers

Doctors learn from a speaker in a seminar for further training.jpg

Based on rigorous, prospective clinical studies

Although our technology addresses the whole-body milieu and has applications throughout medicine, our products (predictive senescence-based algorithms) are derived from rigorous clinical studies and optimized for specific clinical decision points.

Image by Testalize.me

Discovered at Duke and
Johns Hopkins

The predictive value of senescence in cardiac surgery was discovered in a real-world, observational study at Johns Hopkins and Duke.

Concentrating surgeons performing operation in operating room.jpg

Multi-Center Validation Study Ongoing

A large clinical validation study, GUARD-AKI, is ongoing at Johns Hopkins, WakeMed Heart and Vascular, and Hoag Memorial Hospital with completion expected in early 2022. 

What the Experts Say

“The risk is in the patient but known risk factors are worthless. I played a game and tried to guess which patients would develop AKI and I was wrong all the time”
(Cardiac Surgeon and ERAS Cardiac Executive Committee Member)

“Renal insufficiency is probably one of the highest risk things in our patients.  We all have tremendous respect for - or fear almost - of renal insufficiency” (Cardiac Surgeon)

“If there were a test that would allow us to know that certain patients really were at very high risk for renal failure, yeah, we would try to do a lot of things differently than we might normally do... I would definitely use it” (Cardiac Surgeon)

bottom of page